U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C22H21FN4O.ClH
Molecular Weight 412.888
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PRUVANSERIN HYDROCHLORIDE

SMILES

Cl.FC1=CC=C(CCN2CCN(CC2)C(=O)C3=CC=CC4=C3NC=C4C#N)C=C1

InChI

InChIKey=UYGNZRVLPYZLTF-UHFFFAOYSA-N
InChI=1S/C22H21FN4O.ClH/c23-18-6-4-16(5-7-18)8-9-26-10-12-27(13-11-26)22(28)20-3-1-2-19-17(14-24)15-25-21(19)20;/h1-7,15,25H,8-13H2;1H

HIDE SMILES / InChI
Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula C22H21FN4O
Molecular Weight 376.4267
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/12892843

Pruvanserin (EMD 281014, LY-2422347) is a selective serotonin 5-HT2A receptor antagonist. Pruvanserin was originated by Merck KGaA. Eli Lilly had been developing pruvanserin, under a global licence from Merck KGaA, for the treatment of primary insomnia and major depressive disorder. Phase II trials were completed in the US, Hungary and Spain. However, development appears to have been discontinued.

CNS Activity

Originator

Approval Year

Unknown
139594
Targets

Targets

Primary TargetPharmacologyConditionPotency
Antagonist
2778
 0.35 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Phase II
1132
Unknown

Approved Use

Unknown
Primary
Phase II
1132
Unknown

Approved Use

Unknown
Sourcing

Sourcing

Vendor/AggregatorIDURL
Compound Cloud
6433122
Compound Cloud
9887933
Hangzhou Yuhao Chemical Technology
RT9796
MolPort
MolPort-035-765-739
https://www.molport.com/shop/molecule-link/MolPort-035-765-739
Molnova
M14512
https://www.molnova.com/en/serch-list.html?keywords=M14512
Molnova
M14513
https://www.molnova.com/en/serch-list.html?keywords=M14513
MuseChem
R042206
https://www.musechem.com/product/R042206.html
Tocris
4470
https://www.tocris.com/search.php?Type=QuickSearch&Value=4470
Toronto Research Chemicals
P839050
https://www.trc-canada.com/product-detail/?CatNum=P839050
eMolecules
48884680
https://orderbb.emolecules.com/search/#?query=48884680
eMolecules
72980624
https://orderbb.emolecules.com/search/#?query=72980624
PubMed

PubMed

TitleDatePubMed
EMD 281014, a new selective serotonin 5-HT2A receptor antagonist.
2003 Jul 25
5-HT(2A) inverse-agonists for the treatment of insomnia.
2008
Patents

Patents

07312342
2
07981897
2
08188087
2
20040063723
2

Sample Use Guides

In Vivo Use Guide
Eli Lilly had completed a multicentre phase II trial of pruvanserin in the US (9951; H9U-MC-MDBD; NCT00259311). The trial assessed the safety and efficacy of 5 and 15mg doses versus placebo in approximately 400 patients with primary insomnia.
Route of Administration: Oral
In Vitro Use Guide
Pruvanserin (EMD 281014, LY-2422347) (10–40 nM) dose-dependently inhibited human platelet aggregation in vitro
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:29:19 GMT 2023
Edited
by admin
on Fri Dec 15 15:29:19 GMT 2023
Record UNII
AWA682DH9Z
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PRUVANSERIN HYDROCHLORIDE
USAN  
USAN  
Official Name English
7-{4-[2-(4-fluorophenyl)ethyl]piperazine-1-carbonyl}-1H-indole-3-carbonitrile, monohydrochloride
Systematic Name English
7-(4-(2-(4-FLUOROPHENYL)ETHYL)PIPERAZINE-1-YLCARBONYL)-1H-INDOLE-3-CARBONITRILE HYDROCHLORIDE
Systematic Name English
LSN-2420586
Code English
EMD-281014
Code English
PRUVANSERIN HYDROCHLORIDE [USAN]
Common Name English
LY-2422347 HYDROCHLORIDE
Code English
LSN2420586
Code English
LY-2422347 HCL
Code English
PRUVANSERIN HCL
Common Name English
PIPERAZINE, 1-((3-CYANO-1H-INDOL-7-YL)CARBONYL)-4-(2-(4-FLUOROPHENYL)ETHYL)-, MONOHYDROCHLORIDE
Systematic Name English
LY2422347 HCL
Code English
Classification Tree Code System Code
NCI_THESAURUS C66885
Created by admin on Fri Dec 15 15:29:19 GMT 2023 , Edited by admin on Fri Dec 15 15:29:19 GMT 2023
Code System Code Type Description
FDA UNII
AWA682DH9Z
Created by admin on Fri Dec 15 15:29:19 GMT 2023 , Edited by admin on Fri Dec 15 15:29:19 GMT 2023
PRIMARY
PUBCHEM
9887933
Created by admin on Fri Dec 15 15:29:19 GMT 2023 , Edited by admin on Fri Dec 15 15:29:19 GMT 2023
PRIMARY
EPA CompTox
DTXSID00196134
Created by admin on Fri Dec 15 15:29:19 GMT 2023 , Edited by admin on Fri Dec 15 15:29:19 GMT 2023
PRIMARY
CAS
443144-27-2
Created by admin on Fri Dec 15 15:29:19 GMT 2023 , Edited by admin on Fri Dec 15 15:29:19 GMT 2023
PRIMARY
NCI_THESAURUS
C72835
Created by admin on Fri Dec 15 15:29:19 GMT 2023 , Edited by admin on Fri Dec 15 15:29:19 GMT 2023
PRIMARY
USAN
SS-43
Created by admin on Fri Dec 15 15:29:19 GMT 2023 , Edited by admin on Fri Dec 15 15:29:19 GMT 2023
PRIMARY
SMS_ID
300000044579
Created by admin on Fri Dec 15 15:29:19 GMT 2023 , Edited by admin on Fri Dec 15 15:29:19 GMT 2023
PRIMARY
ChEMBL
CHEMBL1215661
Created by admin on Fri Dec 15 15:29:19 GMT 2023 , Edited by admin on Fri Dec 15 15:29:19 GMT 2023
PRIMARY
Related Record Type Details
Structure of PRUVANSERIN
PARENT -> SALT/SOLVATE
Related Record Type Details
Structure of PRUVANSERIN
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966